Grape King BioTPE:1707 -0.11%78 ROA % is 11.77% as of Dec. 2025, which is 15% above its 10-year median of 10.21. GuruFocus rates TPE:1707 with a GF Score™ of 78/100 and a GF Value™ of NT$144.03 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Grape King Bio ranks better than 76.32% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Grape King Bio's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$1,779 Mil.
Grape King Bio's average Total Assets over the quarter that ended in Dec. 2025 was NT$15,114 Mil. Therefore, Grape King Bio's annualized ROA % for the quarter that ended in Dec. 2025 was 11.77%.
The historical rank and industry rank for Grape King Bio's ROA % or its related term are showing as below:
TPE:1707'
s ROA % Range Over the Past 10 Years
Min: 7.84 Med: 10.21 Max: 14.28
Current: 8.08
During the past 13 years, Grape King Bio's highest ROA % was 14.28%. The lowest was 7.84%. And the median was 10.21%.
TPE:1707's ROA % is ranked better than 76.32% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 2.74
vs TPE:1707: 8.08
Grape King Bio (TPE:1707) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Grape King Bio ROA % Related Terms
Grape King Bio ROA % Historical Data
* Premium members only.
The historical data trend for Grape King Bio's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grape King Bio ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's ROA % distribution charts can be found below:
* The bar in red indicates where Grape King Bio's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Grape King Bio (TPE:1707) has a ROA % of 11.77% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Grape King Bio and its competitors. This is 15% above median its historical median of 10.21. Over the past decade, Grape King Bio's ROA % has ranged from 7.84 to 14.28. According to the industry distribution chart, Grape King Bio ranks #238 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 23.7%.
Is Grape King Bio's ROA % too high?
Grape King Bio's current ROA % of 11.77% is 15% above median its 10-year median of 10.21. Over the past 10 years, this metric has ranged from a low of 7.84 to a high of 14.28. The Drug Manufacturers industry median ROA % is 2.74. Grape King Bio's value of 11.77% is 329.6% above this industry median. Based on the distribution chart, Grape King Bio ranks #238 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Grape King Bio has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Grape King Bio ranks #238 out of 1005 companies for ROA %. This places Grape King Bio in the top 24% of its industry — outperforming the majority of peers. The industry median ROA % is 2.74. Grape King Bio's value of 11.77% is 329.6% above this benchmark. Historically, Grape King Bio's own ROA % has ranged from 7.84 to 14.28 over the past decade. While the company's 10-year median is 10.21 vs. the industry median of 2.74, Grape King Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.74, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grape King Bio's current ROA % of 11.77% is 329.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Grape King Bio and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grape King Bio's current ROA % is 11.77%, which is 15% above median its own 10-year median of 10.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Possible Value Trap. The stock's GF Value™ is NT$144.03, compared to a current price of NT$91.00 — trading 36.8% below its estimated fair value. The current ROA % is 11.77%, which is 15% above median its 10-year median of 10.21 and 329.6% above the Drug Manufacturers industry median of 2.74. Grape King Bio's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current ROA % is 11.77% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grape King Bio (TPE:1707) Overvalued in 2026?
Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued.
The current stock price of NT$91.00 is trading 36.8% below its estimated GF Value™ of NT$144.03.
GuruFocus considers Grape King Bio to be Possible Value Trap.
Key valuation signals for TPE:1707:
ROA %: 11.77% (15% above median its 10-year median of 10.21)
GF Value™: NT$144.03 vs. price of NT$91.00 (36.8% below fair value)
Industry Position: 329.6% above the Drug Manufacturers median (#238 of 1005)
No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
78GF Score
Get the complete analysis for TPE:1707
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1707 has been successfully added to your 
